Henry Kao

Q: What is Henry Kao email address?

Email Henry Kao at hkao23@gmail.com and henry.kao@roche.com. This email is the most updated Henry Kao email found in 2026.

Q: How to contact Henry Kao?

To contact Henry Kao send an email to hkao23@gmail.com or henry.kao@roche.com. (updated on November 04, 2024)

Group Leader, Translational Medicine, Immuno-oncology at Astellas Pharma | Cambridge, Massachusetts, United States

About Henry Kao

Henry Kao is a distinguished Senior Biomarker Leader at Roche, where he has been instrumental in advancing the field of oncology through his expertise in translational research and clinical biomarkers. With a strong foundation in tumor immunology and a comprehensive understanding of both small and large molecules, Henry has successfully led key projects that bridge the gap between laboratory discoveries and clinical applications. His current role involves spearheading the biomarker strategy for Tobemstomig, focusing on the development and validation of innovative T cell bispecifics and targeted radio-immune therapeutics. These cutting-edge therapies are currently being evaluated in early-stage oncology trials, showcasing Henry's commitment to pioneering transformative treatments for cancer patients.

Prior to his current position, Henry served as the Head of the Biomarker Group in New York City, where he cultivated a high-performing team dedicated to advancing biomarker discovery and implementation in clinical settings. His leadership style emphasizes change management and flawless execution, ensuring that projects are delivered on time and meet the rigorous standards of the pharmaceutical industry. Henry's extensive skill set includes quantitative research, clinical research methodologies, and a deep understanding of molecular oncology, which he leverages to drive drug development from target discovery through to Phase 1-3 trials.

Henry's proficiency in utilizing advanced techniques such as confocal microscopy and animal models further enhances his ability to generate robust data that informs clinical decision-making. As a thought leader in the field, he remains committed to fostering collaboration across multidisciplinary teams, ultimately aiming to improve patient outcomes through innovative biomarker-driven therapies.

Henry Kao Work